5月19日中银创新医疗混合C净值增长0.89%，今年来累计上涨36.08%

Group 1 - The core point of the article highlights the performance of the Zhongyin Innovation Medical Mixed Fund C, which has shown a net value of 1.6131 yuan, with a growth of 0.89% [1] - The fund's performance over the past month has yielded a return of 3.96%, ranking 2826 out of 4687 in its category; over the past six months, it has achieved a return of 31.50%, ranking 72 out of 4527; and since the beginning of the year, it has returned 36.08%, ranking 41 out of 4580 [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed Fund C was established on October 30, 2020, and as of March 31, 2025, it has a total scale of 1.454 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held positions at various financial institutions, including as a stock research manager at Taikang Asset Management and as a senior researcher at Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund C since July 1, 2022, and has also taken on managerial roles for other funds within the company [2]